CytRx (CYTR) Complets Enrollment in Aldoxorubicin Phase 3 as STS Treatment
Tweet Send to a Friend
CytRx (NASDAQ: CYTR) announced that it has reached its enrollment target of 400 patients for the company's pivotal global Phase ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
